or Try an Advanced Search...

    Technical Analysis for JAGX - Jaguar Animal Health, Inc.

    Grade Last Price % Change Price Change
    F 3.48 -2.79% -0.10
    JAGX closed down 2.79 percent on Monday, July 1, 2024, on 43 percent of normal volume.
    5 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical JAGX trend table...
    Date Alert Name Type % Chg
    Bollinger Band Squeeze Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    BB Squeeze + Lower Band Touch Range Contraction 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    Bollinger Band Squeeze Range Contraction -2.79%
    Narrow Range Bar Range Contraction -2.79%
    Doji - Bullish? Reversal -2.79%
    20 DMA Resistance Bearish -3.87%
    180 Bearish Setup Bearish Swing Setup -3.87%
    Older End-of-Day Signals for JAGX ...

       Recent Intraday Alerts

    Alert Time
    Lower Bollinger Band Support about 9 hours ago
    Down 3% about 9 hours ago
    Fell Below Lower Bollinger Band about 9 hours ago
    Down 2 % about 9 hours ago
    Fell Below Previous Day's Low about 9 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    JAGX Chart by TradingView
    Basic chart:

    Profile

    Jaguar Animal Health, Inc. Description

    Jaguar Animal Health, Inc., a development-stage animal health company, focuses on developing and commercializing gastrointestinal products for companion and production animals. The company's lead prescription drug product candidate includes Canalevia, a canine-specific formulation of Crofelemer for the treatment of CID and general acute watery diarrhea in dogs. It is also developing Crofelemer to treat acute colitis in horses and general acute watery diarrhea in cats; Neonorm, an enteric-coated tablet for scours in preweaned dairy calves, as well as other animal species, such as horses, goats, and sheep; and other product candidates, including Virend and NP-500. The company was founded in 2013 and is headquartered in San Francisco, California. Jaguar Animal Health, Inc. is a subsidiary of Napo Pharmaceuticals, Inc.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Gastrointestinal Animal Health Dog Gastroenterology Prescription Drugs Colitis Drug Products Diarrhea Gastrointestinal Tract Gastrointestinal Products

    Is JAGX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 26 Jaguar Health regains compliance with Nasdaq's listing rule
    Jun 26 Jaguar Health Regains Compliance with Nasdaq's Bid Price Requirement
    Jun 21 Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders
    Jun 12 Jaguar Health slips after update on anti-diarrheal therapy
    Jun 12 Jaguar Health to Report Pivotal Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer on or Before July 23, 2024
    Jun 7 Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    May 29 Jaguar Health Executes Out-License Deal with Joint Venture Magdalena Biosciences for Botanical Drug Candidate for Schizophrenia
    May 28 Investigator-Initiated Trial of Jaguar Health’s Crofelemer Yields Positive Results for Functional Diarrhea
    May 23 Jaguar Health extends losses as reverse stock split takes effect
    May 23 Jaguar Health to Initiate Commercial Footprint in Cancer Supportive Care at American Society of Clinical Oncology (ASCO) Annual Meeting with Exhibit Booth for FDA-Approved Gelclair Oral Mucositis Product
    See more JAGX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 41.76
    52 Week Low 3.072
    Average Volume 874,967
    200-Day Moving Average 10.73
    50-Day Moving Average 8.74
    20-Day Moving Average 3.81
    10-Day Moving Average 3.77
    Average True Range 0.73
    RSI (14) 26.47
    ADX 43.32
    +DI 15.05
    -DI 31.97
    Chandelier Exit (Long, 3 ATRs) 3.02
    Chandelier Exit (Short, 3 ATRs) 5.39
    Upper Bollinger Bands 4.16
    Lower Bollinger Band 3.46
    Percent B (%b) 0.02
    BandWidth 18.25
    MACD Line -1.17
    MACD Signal Line -1.44
    MACD Histogram 0.266
    Fundamentals Value
    Market Cap 176.63 Million
    Num Shares 50.8 Million
    EPS -0.87
    Price-to-Earnings (P/E) Ratio -4.00
    Price-to-Sales 0.46
    Price-to-Book 3.12
    PEG Ratio -0.02
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 3.84
    Resistance 3 (R3) 3.87 3.77 3.78
    Resistance 2 (R2) 3.77 3.68 3.76 3.76
    Resistance 1 (R1) 3.63 3.63 3.58 3.60 3.74
    Pivot Point 3.53 3.53 3.51 3.52 3.53
    Support 1 (S1) 3.39 3.44 3.34 3.36 3.22
    Support 2 (S2) 3.29 3.39 3.28 3.20
    Support 3 (S3) 3.15 3.29 3.18
    Support 4 (S4) 3.12